The variation of faecal calprotectin after 3 months of anti-TNF therapy is a predictor of sustained clinical remission in patients with Crohn's disease - Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte Accéder directement au contenu
Poster De Conférence Année : 2018

The variation of faecal calprotectin after 3 months of anti-TNF therapy is a predictor of sustained clinical remission in patients with Crohn's disease

Fichier non déposé

Dates et versions

hal-02736175 , version 1 (02-06-2020)

Identifiants

  • HAL Id : hal-02736175 , version 1
  • PRODINRA : 448733
  • WOS : 000427318901281

Citer

E. Sollelis, R. Minet Quinard, G. Bouguen, Marion Goutte, F. Goutorbe, et al.. The variation of faecal calprotectin after 3 months of anti-TNF therapy is a predictor of sustained clinical remission in patients with Crohn's disease. Congress of ECCO - European Crohn's and Colitis Organisation, 2018, Oxford, United Kingdom. Oxford University Press, Journal of Crohn's and Colitis, 12, 2018, Congress of ECCO - European Crohn's and Colitis Organisation. ⟨hal-02736175⟩
15 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More